Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Paliperidone Palmitate

FDA-approved product (suspension, extended release, intramuscular), marketed as Erzofri, Invega Hafyera, Invega Sustenna and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Paliperidone Palmitate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Mental or behavioural disorder
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antipsychotics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA67.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli51.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae45.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Paliperidone Palmitate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Paliperidone Palmitate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Bioequivalence Study of PP3M in Patients With Schizophrenia

    NCT07493551 · start 2024-10-09

    Registered record
    Registry ID
    NCT07493551
    Conditions
    Schizophrenia
    Interventions
    Paliperidone Palmitate Injection (3M)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-10-09
    Completion
    2026-12-31
    Enrolment
    260

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPaliperidone Palmitate Injection (3M)
    PhaseNot applicable
    Registry statusRecruiting

  • Bioequivalence Study of Long-Acting Paliperidone Palmitate in Patients With Schizophrenia

    NCT07268430 · start 2023-12-18

    Registered record
    Registry ID
    NCT07268430
    Conditions
    Schizophrenia
    Interventions
    Paliperidone Palmitate Injection(PP1M); Paliperidone Palmitate Injection(PP1M)(Reference Group)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-12-18
    Completion
    2024-12-25
    Enrolment
    256

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPaliperidone Palmitate Injection(PP1M); Paliperidone Palmitate Injection(PP1M)(Reference Group)
    PhaseNot applicable
    Registry statusCompleted

  • Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis

    NCT06060886 · start 2023-11-01

    Registered record
    Registry ID
    NCT06060886
    Conditions
    Schizophrenia; Treatment-resistant Schizophrenia; Side Effect; Lipid Metabolism Disorders; Diabetes; NAFLD; Psychosis
    Interventions
    Aripiprazole; Paliperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-11-01
    Completion
    2025-12-31
    Enrolment
    244

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Treatment-resistant Schizophrenia; Side Effect; Lipid Metabolism Disorders +3 more
    InterventionAripiprazole; Paliperidone
    PhasePhase 4
    Registry statusUnknown

  • Risk of Breakthrough Symptoms With Long-Acting Injectable Medications

    NCT05473741 · start 2023-01-11

    Registered record
    Registry ID
    NCT05473741
    Conditions
    Schizophrenia; Schizophrenia Relapse
    Interventions
    Second Generation Long-Acting Injectable Antipsychotic Medications
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-01-11
    Completion
    2025-10-27
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizophrenia Relapse
    InterventionSecond Generation Long-Acting Injectable Antipsychotic Medications
    PhaseNot recorded
    Registry statusCompleted

  • "Extended" (Alternate Day) Antipsychotic Dosing

    NCT04478838 · start 2022-06-06

    Registered record
    Registry ID
    NCT04478838
    Conditions
    Schizophrenia and Related Disorders; Drug Administration Schedule; Drug Therapy; Antipsychotic Agents
    Interventions
    Risperidone; Olanzapine; paliperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-06-06
    Completion
    2028-09-30
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia and Related Disorders; Drug Administration Schedule; Drug Therapy; Antipsychotic Agents
    InterventionRisperidone; Olanzapine; paliperidone
    PhasePhase 4
    Registry statusRecruiting

  • Relative Bioavailability of LY03010 Compared to Listed Drug

    NCT04922593 · start 2021-01-13

    Registered record
    Registry ID
    NCT04922593
    Conditions
    Schizophrenia; Psychotic Disorders; Mood Disorders; Schizophrenia Spectrum; Mental Disorders; Antipsychotic Agents; Tranquilizing Agents; Central Nervous System Depressants; Physiological Effects of Drugs; Psychotropic Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action
    Interventions
    LY03010; paliperidone palmitate; INVEGA SUSTENNA
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-01-13
    Completion
    2022-04-15
    Enrolment
    281

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Psychotic Disorders; Mood Disorders; Schizophrenia Spectrum +8 more
    InterventionLY03010; paliperidone palmitate; INVEGA SUSTENNA
    PhasePhase 1
    Registry statusCompleted

  • A Study of Paliperidone Palmitate 6-Month Formulation

    NCT04072575 · start 2019-09-19

    Registered record
    Registry ID
    NCT04072575
    Conditions
    Schizophrenia
    Interventions
    PP6M injection Dose 1; PP6M injection Dose 2
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-09-19
    Completion
    2022-05-03
    Enrolment
    178

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPP6M injection Dose 1; PP6M injection Dose 2
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities

    NCT03713658 · start 2018-10-18

    Registered record
    Registry ID
    NCT03713658
    Conditions
    Schizophrenia
    Interventions
    Risperidone 3 mg; Paliperidone Palmitate 50 mg eq.; Paliperidone Palmitate 75 mg eq.; Paliperidone Palmitate 100 mg eq.; Paliperidone Palmitate 150 mg eq.; Paliperidone Palmitate 175 mg eq.; Paliperidone Palmitate 263 mg eq.; Paliperidone Palmitate 350 mg eq.; Paliperidone Palmitate 525 mg eq.
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-10-18
    Completion
    2019-12-02
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionRisperidone 3 mg; Paliperidone Palmitate 50 mg eq.; Paliperidone Palmitate 75 mg eq.; Paliperidone Palmitate 100 mg eq. +5 more
    PhasePhase 4
    Registry statusCompleted

  • A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal

    NCT03666715 · start 2018-08-07

    Registered record
    Registry ID
    NCT03666715
    Conditions
    Schizophrenia
    Interventions
    Oral Antipsychotics (OAPs); Paliperidone Palmitate 1-Month Formulation (PP1M)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-08-07
    Completion
    2021-05-31
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionOral Antipsychotics (OAPs); Paliperidone Palmitate 1-Month Formulation (PP1M)
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

    NCT03557931 · start 2018-07-13

    Registered record
    Registry ID
    NCT03557931
    Conditions
    Schizophrenia
    Interventions
    ASP4345; placebo; risperidone; quetiapine; olanzapine; ziprasidone; aripiprazole; brexpiprazole; paliperidone; lurasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-07-13
    Completion
    2019-10-21
    Enrolment
    233

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionASP4345; placebo; risperidone; quetiapine +6 more
    PhasePhase 2
    Registry statusCompleted

  • The Effect of a Community-based LAT-treated Management Model on the Violence Risk of Patients With Schizophrenia

    NCT03434210 · start 2018-05-05

    Registered record
    Registry ID
    NCT03434210
    Conditions
    Schizophrenia
    Interventions
    LAT-treated Community Model; care as usual
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2018-05-05
    Completion
    2020-10
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionLAT-treated Community Model; care as usual
    PhaseNot applicable
    Registry statusUnknown

  • A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This Treatment

    NCT03425552 · start 2018-03-11

    Registered record
    Registry ID
    NCT03425552
    Conditions
    Schizophrenia
    Interventions
    Paliperidone; Paliperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2018-03-11
    Completion
    2019-05-02
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPaliperidone; Paliperidone
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation

    NCT02713282 · start 2016-04-28

    Registered record
    Registry ID
    NCT02713282
    Conditions
    Schizophrenia
    Interventions
    Paliperidone palmitate 3 month formulation (PP3M)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-04-28
    Completion
    2018-03-26
    Enrolment
    306

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPaliperidone palmitate 3 month formulation (PP3M)
    PhasePhase 3
    Registry statusCompleted

  • Non-Interventional Study of Participants With Newly Diagnosed Schizophrenia Treated With Paliperidone Palmitate

    NCT02532842 · start 2015-07

    Registered record
    Registry ID
    NCT02532842
    Conditions
    Schizophrenia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-07
    Completion
    2015-09
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

    NCT02462473 · start 2015-05

    Registered record
    Registry ID
    NCT02462473
    Conditions
    Schizophrenia; Schizoaffective Disorder
    Interventions
    Aripiprazole; Olanzapine; Paliperidone; Quetiapine; Risperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-05
    Completion
    2016-01
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder
    InterventionAripiprazole; Olanzapine; Paliperidone; Quetiapine +1 more
    PhasePhase 2
    Registry statusTerminated